Skip to main content

Table 2 Associations of neutropenia with acute respiratory distress syndrome risk, acute kidney injury risk, and mortality

From: Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsis

 

Standardized risk, % (95 % CI)a

    

Outcomes

Neutropenic

Non-neutropenic

Unadjusted RRb (95 % CI)

p

Adjusted RRb (95 % CI)

p

ARDSc

36 % (27, 44 %)

40 % (36, 43 %)

1.09 (0.85, 1.40)

0.51

0.90 (0.70, 1.17)

0.42

AKId

54 % (44, 64 %)

42 % (38, 46 %)

1.39 (1.15, 1.69)

0.002

1.28 (1.04, 1.57)

0.03

30-day mortalitye

44 % (36, 53 %)

42 % (39, 46 %)

1.29 (1.05, 1.58)

0.03

1.05 (0.85, 1.31)

0.65

60-day mortalitye

52 % (43, 61 %)

46 % (43, 49 %)

1.34 (1.12, 1.60)

0.004

1.13 (0.93, 1.37)

0.23

  1. CI confidence interval, RR relative risk, ARDS acute respiratory distress syndrome, AKI acute kidney injury, APACHE acute physiology and chronic health evaluation
  2. aStandardized risks and 95 % confidence intervals by neutropenic status were determined using post-estimation marginal analyses of adjusted multivariable logistic regression models
  3. bRR and 95 % confidence intervals were estimated using post-estimation marginal analyses of logistic regression models
  4. cFinal ARDS logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions, white blood cell, and arterial blood gas components
  5. dFinal AKI logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of diabetes mellitus, history of congestive heart failure, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions, white blood cell, and renal components
  6. eFinal mortality logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of diabetes mellitus, history of congestive heart failure, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions and white blood cell components